Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound sirolimus
- Development stage
- Unknown
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Albumin-bound sirolimus (HB1901) is a nanoparticle albumin-bound (nab) formulation of the mTOR inhibitor sirolimus, developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. This intravenous formulation is designed to enhance the delivery and therapeutic index of sirolimus compared to traditional oral formulations. It is currently in Phase III clinical development for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, specifically in patients who have previously received CDK4/6 inhibitor therapy. By inhibiting the mTOR pathway, the drug aims to overcome resistance to endocrine therapy. In clinical trials, it is frequently evaluated in combination with agents such as fulvestrant. Beyond breast cancer, it is also being investigated for other indications, including malignant perivascular epithelioid cell tumors (PEComa) and solid tumors harboring TSC1 or TSC2 genetic alterations.
- Brand names
- Fyarro
- Other names
- sirolimus for injection (albumin-bound)nanoparticle albumin-bound sirolimus
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on albumin-bound sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound sirolimus.